

## **NEW CONCEPTS IN TRANSLATIONAL CARDIAC RESEARCH**

### **Lost in Translation: Issues in Translating Basic Research to Clinical Practice**

*Peter M. Buttrick*, University of Colorado, Denver, U.S.A

### **Structural Biological Approach to Cardiovascular Diseases**

*Hidezo Mori*, National Cardiovascular Center Research Institute, Osaka Japan

### **Parallels between the Neurodegenerative and Cardiovascular Diseases**

*Jeffrey Robbins*, Children's Hospital Research Foundation, Cincinnati, OH, U.S.A.

### **Lipoprotein Autoimmunity as a Novel Target for Treatment of Cardiovascular Disease**

*Jan Nilsson*, University Hospital MAS, Malmo, Sweden

### **Role of NO in the Control of Mitochondrial Function in Cardiovascular Disease**

*Thomas H. Hintze*, New York Medical College, Valhalla, NY, U.S.A.

### **Evidence-Based Alternative and Complementary Therapies for CVD**

*Maura Paul-Labrador*, Cedars-Sinai Medical Center, Los Angeles, CA, U.S.A.

### **Selective Nuclear Receptor Modulation in Cardiometabolic Disease**

*Ulrich Kintscher*, Universitätsmedizin Berlin, Berlin, Germany

### **Endogenous Secretory RAGE: A Potential Target for Cardiovascular Diseases and Metabolic Syndrome**

*Hidenori Koyama*, Osaka City University Graduate School of Medicine, Osaka, Japan

### **Subtype-Specific $\beta$ -Adrenergic Receptor Signaling In the Heart**

*Rui-Ping Xiao*, National Institute on Aging, NIH, Baltimore, MD, U.S.A

### **Different Signaling Pathways in Cardiomyopathy Resulting from Chronically Enhanced Beta-Adrenergic Receptive Signaling**

*Stephen F. Vatner*, New Jersey Medical School, Newark, NJ, U.S.A.

## **ENDOTHELIAL BIOMEDICINE: NEW OPPORTUNITIES FOR DIAGNOSIS AND TREATMENT**

### **The Biology of Endothelial Progenitor Cells**

*Hyo-Soo Kim*, Seoul National University Hospital, Seoul, Korea

### **Vascular Progenitor Cells - Putative Role in Atherosclerosis**

*Noel M. Caplice*, Mayo Clinic, Rochester, MN, U.S.A.

### **Endothelial Dysfunction in Ischemic Heart Disease: Ready for the Clinician Use?**

*Pasquale Perrone-Filardi*, Federico II University, Naples, Italy

### **Endothelial Biomedicine and Cardiovascular Health: Unique Opportunities for the 21st Century**

*George A. Mensah*, Center for Disease Control and Prevention, Atlanta, GA, U.S.A.

### **Coronary Endothelial Dysfunction in Left Ventricular Hypertrophy: Mechanisms and Treatment**

*Louis P. Perrault*, Montreal Heart Institute, Montreal, Quebec, Canada

### **Flow-Mediated Dilation and Arterial Stiffness: Are Really Useful Clinical Indices?**

**Spyridon Koulouris**, Evangelismos Hospital, Athens, Greece  
**Diabetes and Arteriosclerosis - The Role of Endothelial Dysfunction**  
**Nikolaus Marx**, University of Ulm, Germany

## **OXIDATIVE STRESS AND ANTI-OXIDANT THERAPY**

**Nitric Oxide / Nitroxidative Stress Imbalance in the Failing Heart - Nanomedical Approach**  
**Tadeusz Malinski**, Ohio University, Athens, OH, U.S.A.

**Reactive Oxygen Species and Neovascularization**  
**Masuko Ushio-Fukai**, University of Illinois at Chicago, Chicago, IL, USA

**Oxidative Stress, Antioxidants and Atherosclerosis**  
**Shing-Jong Lin**, Taipei Veterans General Hospital, Taipei, Taiwan

**Hifs: New Players in Vascular Redox Signaling**  
**Agnes Gorch**, German Heart Center Munich at the TU Munich, Germany

**Vascular Oxidative Stress: Relative Importance of Pro- and Antioxidant Enzyme Systems**  
**Ulrich Forstermann**, Johannes Gutenberg University, Mainz, Germany

**Oxidative Stress and Extracellular Sod in Cardiovascular Disease**  
**Tohru Fukai**, University of Illinois at Chicago, Chicago, IL, U.S.A.

**Decrease in Il-10/Tnf-alpha Ratio and Increase in Oxidative Stress in Heart Failure**  
**Pawan K. Singal**, University of Manitoba, Winnipeg, Manitoba, Canada

**Hypoxia Inducible Factor-1 in the Heart**  
**Ralph V. Shohet**, University of Hawaii, Honolulu, U.S.A.

## **INFLAMMATION AND ATHEROGENESIS: SESSION 1**

**The Role of Crp in Atherothrombosis**  
**Ishwarlal Jialal**, UC Davis Medical Center, Sacramento, CA, U.S.A.

**Does C-Reactive Protein Orchestrate Inflammation in Acute Coronary Artery Diseases?**  
**Janos G. Filep**, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada

**Origin of Low-Grade Systemic Inflammation: Implications for Vascular Diseases**  
**Doron Aronson**, Rambam Medical Center, Haifa, Israel

**Does C-Reactive Protein Reflect Inflammation of the Atherosclerotic Plaques in Coronary Arteries?**  
**Harisios Boudoulas**, Academy of Athens, Greece

**Prostanoids and Isoprostanoids in Atherogenesis**  
**Domenico Pratico**, University of Pennsylvania, Philadelphia, PA, U.S.A.

**The Role of Antigen-Presenting Cells in Cardiovascular Disease: a Potential Therapeutic Target?**  
**Alexander Niessner**, Medical University of Vienna, Austria

**Diet vs. Infection Atherosclerosis: What Have We Learnt**  
**Salomon Amar**, Boston University School of Dental Medicine, Boston, MA, U.S.A.

## **INFLAMMATION AND ATHEROGENESIS: SESSION 2**

### **The Inflammatory Response in the Neonate and Its' Management**

*Timothy F. Feltes*, Ohio State University, Columbus, Ohio, U.S.A.

### **Immune Response to OXLDL and its Impact in Atherosclerosis**

*Xinghua Zhou*, Karolinska Hospital, Stockholm, Sweden

### **The Anti-Inflammatory and Anti-Atherogenic Effects of Insulin**

*Paresh Dandona*, State University of New York at Buffalo, Buffalo, NY, U.S.A.

### **The Interplay of Dyslipidemia and Inflammation in the Evolution of Atherosclerotic Plaque**

*Andrea Mezzetti*, "G. d'Annunzio" University, Chieti, Italy

## **GENETIC BASIS OF CARDIOVASCULAR DISEASE**

### **Genetic Basis of Polygenic Hypertension**

*Alan Y. Deng*, Centre Hospitalier de l'Universite de Montreal, Quebec, Canada

### **The Role of Variations in the Innate Immune Response in Viral Myocarditis**

*Neil E. Bowles*, University of Utah School of Medicine, Salt Lake City, UT, USA

### **New Insights into the Genetics of Dilated Cardiomyopathies**

*Luisa Mestroni*, University of Colorado Bioscience Park Center, Aurora, CO, USA

### **Genetics of Vasovagal Syncope**

*Robert S. Sheldon*, University of Calgary, Alberta, Canada

### **Pursuing Genes that Contribute to Coronary Artery Disease - An Idea whose Time has Come**

*Robert Roberts*, University of Ottawa Heart Institute, ON, Canada

### **Comprehensive Approaches for Identification of Susceptibility Genes to Myocardial Infarction**

*Mitsuhiro Yokota*, Aichi-Gakuin University, School of Dentistry, Nagoya Japan

### **Clinical Genomic and Proteomic Approaches to Understand Cardiovascular Disease**

*Cam Patterson*, University of North Carolina at Chapel Hill, NC, U.S.A.

## **CARDIAC REPAIR AND REGENERATION: SESSION 1**

### **Myocardial Restoration with Stem Cells and Bioartificial Tissues; Pandora's Box on the Scale**

*Theo Kofidis*, National University Hospital, National University Singapore, Singapore

### **Stem Cells and Vascular Diseases**

*Qingbo Xu*, St. George's Hospital Medical School, London, England

### **Therapeutic Angiogenesis Using VEGF-E/Human PLGF Chimeric Genes**

*Toyooki Murohara*, Nagoya University Graduate School of Medicine, Nagoya, Japan

**Injectable Biomaterials for Myocardial Repair**

*Jonathan Leor*, Sheba Medical Center, Tel Hashomer, Israel

**Labeling of Stem Cells for Noninvasive Delivery and Tracking in Cardiovascular Regenerative Therapy**

*Dara L. Kraitchman*, Johns Hopkins University, Baltimore, MD, U.S.A.

**Human Cardiomyocyte Progenitor Cells Differentiate into Functional Cardiomyocytes in Vitro**

*Pieter A. Doevendans*, University Medical Center Utrecht, The Netherlands

**Skeletal Myoblasts for Chronic Heart Failure**

*Peter Smits*, Medical Center Rijnmond Zuid (MCRZ), Rotterdam, The Netherlands

**CARDIAC REPAIR AND REGENERATION: SESSION 2**

**Progenitor Cells Mobilization in Acute Myocardial Infarction**

*Ilka Ott*, Deutsches Herzzentrum, Munchen, Germany

**Novel Endogenous Myocardial Repair Strategies for the Treatment of Heart Failure**

*Y. Joseph Woo*, University of Pennsylvania School of Medicine, Philadelphia, PA, U.S.A.

**Long-Lasting Plasticity of Slow-Twitch Skeletal Myoblasts with Connexin-43 for the Efficient Engraftment and Functional Improvement of Failing Heart**

*Teruhiko Toyo-oka*, Tohoku University, Aoba-ku, Sendai, Japan

**Unlocking the Mysteries That Govern Vascular Cell Life and Cell Longevity**

*Kenneth Maiese*, Wayne State University School of Medicine, Detroit, MI, U.S.A.

**Therapeutic Angiogenesis in Ischemic Diseases**

*Jeran-Sebastien Silvestre*, Hopital Lariboisiere, Paris, France

**Cell Transplantation to Improve Heart Function: Myogenesis, Angiogenesis or Matrix Modulation**

*Ren-Ke Li*, University of Toronto, Ontario, Canada

**Myocardial Regeneration**

*Roger Laham*, BIDMC/Harvard Medical School, Boston, MA, U.S.A.

**MOLECULAR IMAGING: FILLING THE GAP BETWEEN PATHOPHYSIOLOGY AND CLINICAL ARENA**

**Metabolic Imaging of the Heart: Beyond Anatomy**

*Vasken Dilsizian*, University of Maryland School of Medicine, Baltimore, MD, U.S.A.

**Molecular Imaging in Atherosclerosis**

*Masanori Aikawa*, Brigham & Women's Hospital, Boston, MA, U.S.A.

**Molecular Imaging in Cardiovascular Diseases**

*Elena Aikawa*, Massachusetts General Hospital, Charlestown, MA, U.S.A.

## **BIOMARKERS TODAY**

### **Atherosclerosis Lab Risk Markers Today: Research and Clinical Implications**

*Wolfgang Koenig*, University of Ulm Medical Center, Germany

### **Biomarkers in Unstable Coronary Syndromes**

*Dimitris Tousoulis*, Hippokraton Hospital, Athens, Greece

## **NEW CONCEPTS IN STRESS TESTING AND ECHOCARDIOGRAPHY**

### **Exercise ECG in the Interventional Era: Out of Date or Evergreen?**

*Riccardo Bigi*, University School of Medicine, Milan, Italy

### **Stress Echocardiography and New Technologies**

*Rosa Sicari*, CNR Institution of Clinical Physiology, Pisa, Italy

### **Value and Significance of E/E' by Doppler Echocardiography: More than Meets the Eye?**

*Cristina Pislaru*, Mayo Clinic, Rochester, MN, U.S.A.

### **Role of Myocardial Contrast Echocardiography in Acute Myocardial Infarction**

*Roxy Senior*, Northwick Park Hospital, Harrow, Middlesex, UK

### **Assessing LV Function by Echocardiography: the Challenge Continues**

*Fausto J. Pinto*, University Hospital Sta Maria, Lisbon University, Portugal

### **Three Dimensional Echocardiography 2007**

*Folkert J. Ten Cate*, Thoraxcenter Ba 304, Rotterdam, The Netherlands

### **3D Echocardiography - Clinical Applications and Future Directions**

*Smadar Kort*, Stony Brook University Medical Center, Stony Brook, NY, U.S.A.

## **NOVEL IMAGING TECHNIQUES TO ASSESS CARDIAC PERFUSION, FUNCTION AND VIABILITY**

### **Acute Heart Failure: New Diagnostic and Therapeutical Perspectives**

*Francesco Fedele*, Universita Degli Studi Di Roma "la Sapienza", Roma, Italy

### **The Future of Stress Perfusion Imaging In the Era of CT**

*Rory Hachamovitch*, University of Southern California, Los Angeles, CA, U.S.A.

### **Revascularization in Left Ventricular Systolic Dysfunction: The Role of Viability Testing**

*Panithaya Chareonthaitawee*, Mayo Clinic, Rochester, MN, U.S.A.

## **MULTISLICE CT IN CLINICAL CARDIOLOGY**

### **The Emergence of Cardiovascular CT in Clinical Cardiology**

*Joao A.C. Lima*, Johns Hopkins Hospital, Baltimore, MD, U.S.A.

### **Multi-Slice CT- and Its Role in Clinical Cardiology**

*Stephen Schroeder*, Division of Cardiology, Tuebingen, Germany

**A Comparison between Coronary Angiogram and Multislice CT in Coronary Artery Disease. A Study of 150 Cases**

*Sergio Dalla-Volta*, Universita degli Studi di Padova, Italy

**Considering Coronary Artery Calcium**

*Elizabeth L. Barrett-Connor*, University of California, San Diego, La Jolla. CA, U.S.A.

**Coronary Artery Bypass Grafts and CT Angiography**

*Leonard Kritharides*, Concord Hospital, Concord, Australia

**Is There a Role for CT Coronary Angiography in Clinical Practice?**

*Mario J. Garcia*, Cleveland Clinic Foundation, Cleveland, OH, U.S.A.

**Atherosclerosis Imaging: Where are We and Where are We Going?**

*Sanjay Rajagopalan*, Mount Sinai School of Medicine, New York, NY, U.S.A.

**CARDIAC MRI IN CLINICAL CARDIOLOGY**

**Noninvasive Imaging of Atherothrombosis by MRI**

*Roberto Corti*, University Hospital Zurich, Switzerland

**Assessment of Atheroma Plaque by Cardiac MR and Cardiac CT: Current and Future Clinical Impact**

*Luis J. Jimenez-Borreguero*, Hospital Universitario de la Princesa, Madrid, Spain

**Cardiovascular Magnetic Resonance (CMR) 2007 and Beyond**

*Gerald Pohost*, USC School of Medicine, Los Angeles, U.S.A.

**Magnetic Resonance Imaging Characterization of Advanced Atherosclerotic Plaques**

*Chun Yuan*, University of Washington, Seattle, WA, U.S.A.

**PATHOGENESIS OF ATHEROSCLEROSIS**

**Tissue Factor and Cardiovascular Disease**

*Felix C. Tanner*, University of Zurich, Switzerland

**Role of Lox-1 in Atherosclerosis; Lessons from Knockout Mice**

*Jawahar L. Mehta*, University of Arkansas for Medical Sciences, Little Rock, AR, U.S.A.

**Mast Cells Promote Atherosclerosis by Releasing Pro-Inflammatory Cytokines**

*Guo-Ping Shi*, Brigham and Women's Hospital, Boston, MA, U.S.A.

**Vessel Aging and the Development of Atherothrombosis**

*Paul Holvoet*, The Center for Experimental Surgery and Anesthesiology, Leuven, Belgium

**Cholesteryl Esters From ACAT2 are Atherogenic in Mice and Monkeys**

*Lawrence L. Rudel*, Wake Forest University School of Medicine, Winston-Salem, NC, U.S.A.

**Atherosclerotic Plaque Development at the Strain / Stress Interface**

*Stephanie Lehoux*, INSERM CRC Lariboisiere, Paris, France

## **THE VULNERABLE PLAQUE AND ACUTE CORONARY SYNDROMES**

### **A Role of Coronary Angioscopy for the Detection of Vulnerable Plaques and Vulnerable Patients**

*Yasunori Ueda*, Osaka Police Hospital, Osaka, Japan

### **Thrombus Age in Acute Coronary Syndromes: A Tale of the Old and the New**

*Robert J. de Winter*, Academic Medical Center, Amsterdam, The Netherlands

### **New Approaches to Vulnerable Plaque Detection**

*Robert L. Wilensky*, Hospital of the University of Pennsylvania, Philadelphia, PA, U.S.A.

### **Imaging of the Vulnerable Plaque: Indications, Challenges and Future Directions**

S. David Gertz, St. Luke's Episcopal Hospital, Houston, TX, U.S.A.

## **CARDIOPROTECTIVE MECHANISMS IN MYOCARDIAL ISCHEMIA**

### **Cytoprotective and Cardioprotective Effects of Hydrogen Sulfide**

*Csaba Szabo*, Ikaria Inc., Seattle, WA, U.S.A.

### **DNAZYMES in the Treatment of Cardiovascular Disease**

*Harry Lowe*, University of Sydney, Australia

### **Peptide-Induced Cardioprotection - Insights into Novel Mechanisms**

*Cherry L. Wainwright*, The Robert Gordon University, Aberdeen, United Kingdom

### **Role of Protein Kinase C in Reperfusion Arrhythmias**

*Mohamed Boutjdir*, NY Harbor Healthcare System, Brooklyn, NY, U.S.A.

### **Insulin-Triggered Cell Survival Signaling and its Protection against Myocardial Ischemia / Reperfusion Injury**

*Feng Gao*, Fourth Military Medical University, Xi'an, China

### **Limiting Myocardial Ischemia-Reperfusion Injury: Preconditioning, Postconditioning and Beyond**

*Karin Przyklenk*, University of Massachusetts Medical School, Worcester, MA, U.S.A.

### **Ischemic Pre- and Post-Conditioning: Clinically Relevant or Not?**

*Warren K. Laskey*, University of New Mexico School of Medicine, Albuquerque, NM, U.S.A.

## **INSIGHTS INTO THE TREATMENT OF ACUTE CORONARY SYNDROMES**

### **Management and Outcome of Elderly with ACS**

*Shmuel Gottlieb*, Bikur Cholim Hospital, Jerusalem, Israel

### **Laser Thrombolysis in Acute Ischemic Thrombotic Syndromes - The Impact of Technique on Clinical Outcome**

*On Topaz*, McGuire VA Medical Center, Richmond, VA, U.S.A.

### **Role of ABCIXIMAB in Primary Stenting for Acute Myocardial Infarction**

*David L. Brown*, State University of New York, Stony Brook, NY, U.S.A.

**Prognostic Importance of Bleeding in ACS**

*John W. Eikelboom*, McMaster University, Hamilton, ON, Canada

**New Insights Into The Benefits Of Antiplatelet Therapy In Patients With CAD**

*Nasser M. Lakkis*, Ben Taub General Hospital, Baylor College of Medicine, Houston, TX, U.S.A.

**Facilitated PCI for Acute MI: The Role of Anti-GP IIB/IIIA**

*Leonardo Bolognese*, Azienda Ospedaliera Arezzo, Arezzo, Italy

**NEW DIRECTIONS IN CORONARY INTERVENTIONAL THERAPY**

**Renal Disease Impact on Coronary Interventional Outcomes**

*George W. Vetrovec*, Virginia Commonwealth University, Richmond, VA, U.S.A.

**Development of a Novel Bioabsorbable Polymeric Nanoparticle-Eluting Stent by an Actively-Controlled Multilayer Coating Technology**

*Kensuke Egashira*, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

**Left Main Stenting: Are we there yet?**

*Fayaz Shawl*, Washington Adventist Hospital, Takoma Park, MD, U.S.A.

**Percutaneous Interventional Treatment of Left Main Stenosis. A Critical Appraisal**

*Harald Mudra*, Krankenhaus Munchen Neuperlach, Munchen, Germany

**THE ERA OF DRUG ELUTING STENTS: LIGHTS AND SHADES**

**Cost-Effectiveness of Drug-Eluting Stents**

*Mark J. Eisenberg*, The Jewish General Hospital, Montreal, Quebec, Canada

**The Use of Drug Eluting Stents in Complex Coronary Lesions Anno 2007**

*Henning Kelbaek*, Rigshospitalet & Skejby Hospital, Denmark

**Treatment of in-Stent Restenosis with Drug-Eluting Stents - Insights from Intravascular Ultrasound Findings**

*Thomas M. Schiele*, Universitat Munchen-Innenstadt, Munich, Germany

**Coronary Stent Thrombosis in The Era of Drug-Eluting Stents**

*Raul Moreno*, University Hospital La Paz, Madrid, Spain

**Drug-Eluting Stents: Is the Increased Risk of Stent Thrombosis an Acceptable Clinical Tradeoff for Reduced Restenosis?**

*Sanjay Kaul*, Cedars-Sinai Medical Center, Los Angeles, CA, U.S.A.

**New Drug-Eluting Stents for the Prevention of Late Stent Thrombosis**

*Myung Ho Jeong*, National University Hospital Dong-gu, Gwangju , Korea

**Is Long –Term Safety the “Achilles Heel” of Drug-Eluting Stents**

*Barry F. Uretsky*, University of Texas Medical Branch at Galveston, TX, U.S.A.

## **ADVANCES IN STRUCTURAL INTERVENTIONS**

### **Indications for Percutaneous Closure of PFOs**

*Eric Rosenthal*, Guy's Hospital, London, England

### **Application of Angioscopy for Diagnosis and Treatment of Venous Thromboembolism**

*Takanobu Tomaru*, Toho University Sakura Hospital, Japan

## **TREATMENT OF CAROTID STENOSIS - STATE-OF-THE-ART**

### **Carotid Angioplasty under Protection. Limitations. New Developments**

*Michel Henry*, Nancy, France

### **Embolic Protection during Carotid Stenting with the New Fibernet Device**

*Horst Sievert*, Cardiovascular Center Frankfurt, Germany

### **Carotid Artery Disease: Stent versus Scalpel!**

*Satyendra Giri*, Baystate Medical Education & Research Foundation, Springfield, MA, U.S.A.

## **NEW TREATMENTS OF PERIPHERAL ARTERIAL DISEASE**

### **New Insights into Peripheral Arterial Disease**

*Michael H. Criqui*, University of California San Diego, La Jolla, CA, U.S.A.

### **Endovascular Treatment of Peripheral Arterial Diseases**

*Debabrata D. Mukherjee*, University of Kentucky, Lexington, KY, U.S.A.

### **The Changing Paradigm of Renal Artery Stenosis**

*George A. Stouffer*, University of North Carolina, Chapel Hill, NC, U.S.A.

### **Inter-Relationship of Coronary Artery Disease and Peripheral Arterial Disease**

*Vergheese Mathew*, Mayo Clinic, Rochester, MN, U.S.A.

## **EVOLVING TREATMENT STRATEGIES FOR ISCHEMIC CORONARY DISEASE**

### **Treatment of Stable Angina: What works and What is New?**

*Udho Thadani*, University of Oklahoma HSC, Oklahoma City, OK, U.S.A.

### **ACE2: Potential Target for CV Therapeutics**

*Mohan K. Raizada*, University of Florida, Gainesville, FL, U.S.A.

### **Advances in Pharmacotherapy Of Angina**

*Kanu Chatterjee*, UCSF School of Medicine, San Francisco, CA, U.S.A.

### **Bleeding and Blood Transfusion Issues in Patients with Ischemic Heart Disease**

*Sunil V Rao*, Durham VA Medical Center, NC, U.S.A.

### **Angina: Effective Therapy or a Waste of Time?**

*Greg Barsness*, Mayo Clinic, Rochester, MN, U.S.A.

### **Opportunities with Integrin-Targeted Perfluorocarbon Nanoparticles in Atherosclerosis**

*Gregory M. Lanza*, Washington University, St Louis, MO, U.S.A.

**Coronary Artery Bypass Grafting for Stenotic Lesions caused by Kawasaki Disease**  
*Etsuko Tsuda*, National Cardiovascular Center, Osaka, Japan

## **EPIDEMIOLOGY OF HEART DISEASE**

**CHD and South Asians - The Current Epidemic**  
*Sandeep Gupta*, Whipps Cross and St. Bartholomew's Hospitals, Leytonstone, UK

**Heart Disease in Africa: Is there an Epidemiological Transition?**  
*Patrick J. Commerford*, Groote Schuur Hospital, Cape Town, South Africa

**Clinical Profile and Genetic Basis of Brugada Syndrome in the Chinese Population**  
*Ngai-Shing Mok*, Lai Chi Kok, Kowloon, Hong Kong, China

**Measuring the Quality of Heart Failure Care**  
*Paul A. Heidenreich*, Palo Alto VA Health Care System, Palo Alto, CA, U.S.A.

**Coronary Artery Disease in Asian Indians**  
*Narendra C. Bhalodkar*, Bronx-Lebanon Hospital Center, Bronx, NY, U.S.A.

## **CARDIOVASCULAR RISK ASSESSMENT**

**Why do Men Have More Heart Disease than Women?**  
*Kevin S. Channer*, Royal Hallamshire Hospital, Sheffield, England

**Migraine and Risk of CVD**  
*Tobias Kurth*, Brigham and Women's Hospital, Boston, MA, U.S.A.

**The Role of Aspirin Resistance in the Setting of Coronary Artery Disease**  
*Michael N. Zairis*, Piraeus, Greece

**Aspirin Resistance: Fact or Fallacy?**  
*Lewis C. Becker*, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.

**Mediterranean Diet and Coronary Heart Disease, is Obesity a Link?**  
*Demosthenes B. Panagiotakos*, Harokopio University, Athens, Greece

**Biomarkers of Cardiovascular Risk, Race / Ethnicity and Gender**  
*Michelle A. Albert*, Brigham and Women's Hospital, Boston, MA, U.S.A.

**Personalized Prognosis for Decision-Making: Actualizing the Framingham Dream in the 21st Century**  
*Eugene M. Blackstone*, The Cleveland Clinic, OH, U.S.A.

**Metabolic Syndrome, Subclinical Atherosclerosis, and Cardiovascular Risk**  
*Nathan D. Wong*, University of California, Irvine, CA, U.S.A.

## **LIPOPROTEINS AND CARDIOVASCULAR DISEASE**

**How Low is Too Low? Is There a Limit to Blood Pressure Lowering?**  
*Clive Rosendorff*, VA Medical Center, Bronx, NY, U.S.A.

**Aggressive Lipid Management: LDL Apheresis**

*Donna Polk*, Cedars-Sinai Medical Center, Los Angeles, CA, U.S.A.

**HDL Therapy, Oral APOA-1 Mimetic Peptides**

*Mohamad Navab*, David Geffen School of Medicine at UCLA, Los Angeles, CA, U.S.A.

**Increasing HDL: How a 'Garbage' Truck Turned Into a Vessel-Repair Unit**

*Erik S.G. Stroes*, Academic Medical Center, University of Amsterdam, The Netherlands

**Lipid Storage in Cells; Mechanism and Implications for Cardiovascular Diseases**

*Sven-Olof*, Olofsson Sahlgrenska University Hospital, Goteborg, Sweden

**NOVEL CONCEPTS IN SYSTEMIC AND PULMONARY HYPERTENSION**

**A Vascular Apoptosis-Based Theory for Pulmonary Arterial Hypertension and a Framework for the Development and Translation of Novel Experimental Therapies**

*Evangelos Michelakis*, University of Alberta, Edmonton, Canada

**Clinical Guidelines for the Primary Prevention of Hypertension: Can we do more?**

*Howard Sesso*, Brigham and Women's Hospital, Boston, MA, U.S.A.

**Chronotherapy in Hypertension: Impact on Cardiovascular Risk Reduction**

*Ramon C. Hermida*, E.T.S.I. Telecomunicacion, Vigo (Pontevedra), Spain

**Vascular Signaling in Hypertension - Current Concepts and Future Directions**

*Rhian M. Touyz*, University of Ottawa, ON, Canada

**From Hypertension to Heart Failure: Can We Interrupt the Course**

*Vasilios Papademetriou*, Georgetown University, Washington, DC, U.S.A.

**Human Immunodeficiency Virus-Associated Pulmonary Hypertension: Pathogenesis and Clinical Aspects**

*Giuseppe Barbaro*, University of Rome "La Sapienza" Rome, Italy

**Cardiac Biomarkers in Pulmonary Embolism and Pulmonary Hypertension**

*Ijaz A. Khan*, University of Maryland School of Medicine, Baltimore, MD, U.S.A.

**THE METABOLIC SYNDROME: EMERGING EPIDEMIC OF THE CENTURY?**

**Developmental Programming of Cardiovascular Control by Maternal Nutrition: Influence of Adolescent Obesity**

*David S. Gardner*, University of Cambridge, England

**Targeting Lipoprotein Subclass Abnormalities in the Metabolic Syndrome: New Opportunities for Cardiovascular Risk Reduction**

*Robert S. Rosenson*, Northwestern University, Chicago, IL, U.S.A.

**Metabolic Syndrome in Early Life and its Consequences**

*Gerald S. Berenson*, Tulane Center for Cardiovascular Health, New Orleans, LA, U.S.A.

**Benefits of Tight Glycemic Control during Coronary Revascularization**

*Harold L. Lazar*, Boston Medical Center, MA, U.S.A.

### **Tailoring the Diabetic Platelet**

**Dominick J. Angiolillo**, University of Florida-Shands Jacksonville, FL, U.S.A.

### **Impact of Metabolic Syndrome on Myocardial Perfusion Grade after Primary Percutaneous Coronary Intervention in Patients with Acute ST Elevation Myocardial Infarction**

**Turgay Celik**, Gulhane School of Medicine, Ankara, Turkey

## **GENDER AND HEART DISEASE**

### **Secondary Prevention of CHD in Women**

**Vera Bittner**, University of Alabama at Birmingham, AL, U.S.A.

### **The Direct Implications of Body Fat Mass and Its Topographic Distribution for Cardiovascular Risk in Postmenopausal Women: From Risk to Protection**

**Laszlo B. Tanko**, Center for Clinical and Basic Research, Ballerup, Denmark

### **Sex, Age and Regional Differences of L-Type Calcium Channels in the Heart**

**Guy Salama**, University of Pittsburgh, PA, U.S.A.

## **DILATED CARDIOMYOPATHY: VARIOUS ETIOLOGIES**

### **Alcohol and Cardiovascular Diseases: 2007 Update**

**Arthur L. Klatsky**, Kaiser Permanente Medical Center, Oakland, CA, U.S.A.

### **Peripartum Cardiomyopathy in the US: Definition, Clinical Presentation and Potential Mechanisms**

**Uri Elkayam**, LAC and USC Medical Center, Los Angeles, CA, U.S.A.,

### **What are the New Cancer Therapeutics Doing to the Heart?**

**Thomas Force**, Jefferson Medical College, Philadelphia, PA, U.S.A.

### **New Interventions in the Treatment of Cardiomyopathy Related to Iron-Overload**

**Peter H. Backx**, University of Toronto, Ontario, Canada

### **Obesity and Congestive Heart Failure**

**Martin A. Alpert**, St. John's Mercy Medical Center, St. Louis, MO U.S.A.

### **Viral Induced Cardiomyopathy - Diagnosis and Therapy**

**Heinz-Peter Schultheiss**, University Hospital Benjamin Franklin, Berlin, Germany

### **Mechanisms of HIV-Associated Cardiovascular Disease**

**Changyi Chen**, Baylor College of Medicine, Houston, TX, U.S.A.

### **Role of Viral Infection and Some Inflammatory Cytokines in the Development of Dilated Cardiomyopathy**

**Nodar N. Kipshidze**, Institute of Experimental and Clinical Therapy, Tbilisi, Rep. of Georgia

### **Myocardial Structural Changes in Long-Term Human Severe Sepsis / Septic Shock May Responsible for Cardiac Dysfunction**

**Marcos A. Rossi**, University of Sao Paulo, Ribeirao Preto, S.P. Brazil

### **Coronary Microvascular Dysfunction and Heart Failure: Which Link?**

**Danilo Neglia**, CNR Institute of Clinical Physiology, Pisa, Italy

## **DIASTOLIC HEART FAILURE**

### **Role of Collagen Matrix in the Transition from Hypertrophy to Failure in Hypertension**

*Javier Diez*, University Clinic, Pamplona, Spain

### **Regression of Left Ventricular Hypertrophy and Outcomes**

*Jonathan N. Bella*, Bronx-Lebanon Hospital Center, Bronx, NY, U.S.A.

### **Left Ventricular Hypertrophy in Hypertension: Is Drug Selection Important?**

*Philip R. Liebson*, Rush Presbyterian-St. Luke's Medical Center, Chicago, IL, U.S.A.

### **Diastolic Dysfunction - How to Diagnose, How to Treat**

*Otto M. Hess*, Inselspital, Bern, Switzerland

### **Role of Digoxin in Diastolic Heart Failure**

*Ali Ahmed*, University of Alabama at Birmingham, AL, U.S.A.

### **Role of Phospholipase C Isozymes in Hypertrophy of the Adult Heart**

*Paramjit S. Tappia*, St. Boniface Hospital Research Centre, Winnipeg, Manitoba, Canada

## **VENTRICULAR REMODELING AND HEART FAILURE THERAPY**

### **Metabolic Therapy for the Treatment of Heart Failure**

*Giuseppe M.C. Rosano*, IRCCS San Raffaele, Roma, Italy

### **Risk Assessment in Heart Failure**

*Javed Butler*, Vanderbilt University Medical Center, Nashville, TN, U.S.A.

### **The Role of TGF-Beta Signaling in Healing Myocardial Infarcts - Mechanistic Concepts and Clinical Implications**

*Nikolaos Frangogiannis*, Baylor College of Medicine, Houston, TX, U.S.A.

### **The (Pro)Renin Receptor: A New Addition to the Renin-Angiotensin System?**

*Alexander H.J. Danser*, Erasmus Medical Center, Rotterdam, The Netherlands

### **Chemokines in Cardiovascular Remodeling**

*Christian Weber*, Universitätsklinikum Aachen, Germany

### **Remodeling of the Vasculature in Hypertension: Relation to the Natural History**

*Ernesto L. Schiffrin*, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada

## **MATRIX MODULATION IN HEART FAILURE**

### **Differential Matrix Metalloproteinase Proteomic Profiling in Patients at Risk for Heart Failure: Diagnostic and Prognostic Implications**

*Francis G. Spinale*, Medical University of South Carolina, Charleston, SC, U.S.A.

### **Cardiac Dyssynchrony Induced Inflammation And Extracellular Matrix Degradation**

*Francisco J. Villarreal*, UCSD, La Jolla, CA, U.S.A.

### **Mitochondrial Mechanism of Metalloproteinase Activation in Congestive Heart Failure**

*Suresh C. Tyagi*, University of Louisville School of Medicine, Louisville, KY, U.S.A.

**Pleiotropic Effects of Therapeutic Cardiac Drugs and Interventions on the Extracellular Collagen Matrix: The Good, The Bad and The Ugly**

**Bodh I. Jugdutt**, University of Alberta Hospitals, Edmonton, Alberta, Canada

**CARDIOPROTECTION**

**Beneficial Effects of A 5-HT<sub>2A</sub> Receptor Antagonist in Congestive Heart Failure**

**Naranjan S. Dhalla**, St. Boniface Hospital Research Centre, Winnipeg, Manitoba, Canada

**Protein Kinase C and Heart Disease - from Cardiac Ischemia to Heart Failure**

**Daria Mochly-Rosen**, Stanford University School of Medicine, CA U.S.A.

**Cardioprotective Actions of Adiponectin**

**Noriyuki Ouchi**, Boston University School of Medicine, MA, USA -

**The No-Reflow Phenomenon: Diagnosis and Treatment**

**Leonarda Galiuto**, Catholic University of the Sacred Heart, Rome, Italy

**BIOMARKERS IN HEART FAILURE**

**Serial Biomarkers in Chronic Heart Failure: What Happens over Time**

**Wayne Miller**, Mayo Clinic, Rochester, MN, U.S.A.

**Can NT-PROBNP Levels Help Prevent Cardiovascular Events?**

**Duncan J. Campbell**, St. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia

**PRO-BNP Diagnostic Consideration of Dyspnea in Patients with COPD and / or Left Ventricular Failure**

**Nestor J. Angomachalelis**, Aristotle University School of Medicine, Thessaloniki, Macedonia, Greece

**Heat Shock Protein 60 in Heart Failure: Friend or Foe?**

**Anne A. Knowlton**, University of California, Davis, CA, U.S.A.

**Natriuretic Peptides in the Approach to HF Patients**

**Paulo M. Bettencourt**, Hospital S Joao, Porto, Portugal

**DRUG TREATMENT FOR HEART FAILURE: NEW APPROACHES**

**Aquaretic Agents for Heart Failure**

**Robert E. Hobbs**, The Cleveland Clinic Foundation, OH, U.S.A.

**The Kidney in Heart Failure: A Therapeutic Target**

**John C. Burnett**, Mayo Clinic and Foundation, Rochester, MN, U.S.A.

**Inotropes in Advanced Heart Failure. A Minority Opinion**

**John N. Nanas**, University of Athens, Greece

**Changing Paradigms of Cardiovascular Interventions**

**Hanumanth K. Reddy**, University of Missouri-Columbia, U.S.A.

**Cardiovascular Disease in Renal Failure: What's New?**

*Rene R. Wenzel*, Cardiology & Nephrology-Cardiovascular Research, Zell am See, Austria

**The Impact of Beta Blockers on Central Sleep Apnea in Chronic Heart Failure**

*Akira Tamura*, Oita University, Japan

**Beta-Blockers and Cardiopulmonary Variables in CHF**

*Klaus K. Witte*, Leeds General Infirmary and University of Hull, UK

**Metabolic Modulation in Heart Failure: Diabetes and Beyond**

*W.H. Wilson Tang*, Cleveland Clinic Foundation, OH, U.S.A.

**DEVICES AND SURGICAL THERAPIES FOR HEART FAILURE**

**Patient Selection of Left Ventricular Assist Device Implantation - Endlessly Moving Target**

*Yoshifumi Naka*, College of Physicians and Surgeons, New York, NY, U.S.A.

**Passive Restraining Devices**

*Randall C. Starling*, Cleveland Clinic Foundation, Cleveland, OH, U.S.A.

**Baroreflex Activation Therapy for the Treatment of Heart Failure**

*Hani N. Sabbah*, Henry Ford Heart & Vascular Institute, Detroit, MI, U.S.A.

**Implanted Hemodynamic Monitoring in the Therapy of Heart Failure**

*Robert C. Bourge*, The University of Alabama, Birmingham, AL, U.S.A.

**The Selection of Patients with Heart Failure who Benefit from Cardiac Resynchronization Therapy**

*Maria Vittoria Pitzalis*, East Carolina University, Greenville, NC, U.S.A.

**Percutaneous Left Ventricular Support in the Catheterization Laboratory and Beyond. What can we expect in the Nearby Future?**

*Jose P.S. Henriques*, Academic Medical Center, Amsterdam, The Netherlands

**Heart Retransplantation - Is it a Viable Option and if so, When?**

*Maryl R. Johnson*, University of Wisconsin-Madison, WI, U.S.A

**Pediatric Mechanical Circulatory Support: New Devices and Latest Developments**

*Brian W. Duncan*, The Children's Hospital at the Cleveland Clinic, OH, U.S.A.

**Surgical Options for End-Stage Heart Failure**

*Roland Hetzer*, German Heart Institute, Berlin, Germany

**PERICARDIAL DISEASES**

**Leading Issues and Controversies in Pericardial Disease**

*David H. Spodick*, University of Massachusetts Medical School, Worcester, MA, U.S.A.

**Acute and Recurrent Pericarditis**

*Massimo Imazio*, Maria Vittoria Hospital, Torino, Italy

## **RISK STRATIFICATION FOR SUDDEN CARDIAC DEATH**

### **Fluctuations of ECG and Risk Stratification in Brugada Syndrome**

*Masahiko J. Takagi*, Osaka City University Graduate School of Medicine, Japan

### **Update on Management of Right Ventricular Outflow Tract Tachycardia**

*Rungroj Krittayaphong*, Siriraj Hospital, Bangkok, Thailand

### **Population-Based Analysis of Sudden Cardiac Death: Clinical Implications**

*Sumeet S. Chugh*, Oregon Health and Science University, Portland, OR, U.S.A.

### **How Best to Identify Patients at Risk for Sudden Cardiac Death**

*Michael E. Cain*, Washington University School of Medicine, St. Louis, MO, U.S.A.

### **Current Perspectives in Risk Stratification for Sudden Cardiac Death**

*Dan Wichterle*, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

### **Sudden Cardiac Death in Young Individuals: Clinical and Genetic Investigation of the Family**

*Pascal McKeown*, Queen's University Belfast, Ireland

### **Risk Stratification for Sudden Cardiac Death: Where are we now, where do we need to be?**

*Sana M. Al-Khatib*, Duke Clinical Research Institute, Durham, NC, U.S.A.

## **ADVANCES IN THE MANAGEMENT OF PATIENTS WITH VENTRICULAR ARRHYTHMIAS**

### **Is it Possible to Reduce Hospitalization Costs for Patients Considered at Risk of Serious Arrhythmias?**

*Antonio Martinez-Rubio*, Hosp. de Sabadell -Cardiology, Barcelona, Spain

### **Catheter Ablation of Ventricular Tachycardia Occurring Late After Myocardial Infarction using Substrate Modification**

*Thomas Deneke*, University of Bochum, Germany

### **Rationales, Methods and Preliminary Results of Subcutaneous Only ICDs**

*Riccardo Cappato*, Policlinico San Donato, Milan, Italy

### **ICD Therapy in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy**

*Firat Duru*, University Hospital of Zurich, Switzerland

## **NEW DIAGNOSTIC AND THERAPEUTIC APPROACHES IN ATRIAL FIBRILLATION**

### **Spectral Analysis of AF Electrograms and ECGs**

*Andreas Bollmann*, Good Samaritan Hospital, Los Angeles, CA, U.S.A.

### **Implantable Devices in the Management of Patients with Atrial Fibrillation**

*Carsten W. Israel*, J.W. Goethe University, Frankfurt, Germany

## **ABLATION FOR ATRIAL FIBRILLATION AND SVT**

### **Emerging Techniques for Ablation of Atrial Fibrillation**

*Andrea Natale*, The Cleveland Clinic, Cleveland, OH, U.S.A.

**Atrial Fibrillation and Heart Failure: Role of AVN Ablation and Pacemaker Therapy**  
*Win-Kuang Shen*, Mayo Clinic, Rochester, MN, U.S.A.

**Role of Real-Time Imaging in Ablation of Atrial Fibrillation: Introducing New Imaging Modality**  
*Nasir F. Marrouche*, University of Utah, Health Sciences Center, Salt Lake City UT, USA

**Catheter Ablation of Atrial Fibrillation**  
*Shih-Ann Chen*, Veterans General Hospital, Taipei, Taiwan

**Determinants of Lesion Size during Catheter Cryoablation**  
*Mark A. Wood*, Virginia Commonwealth University, Richmond, VA, U.S.A.

## **HEART FAILURE, ARRHYTHMIAS, AND DEVICES**

**CHF and AF: Who is Guilty**  
*Alessandro Capucci*, Ospedale "Guglielmo da Saliceto", Piacenza, Italy

**Reproducibility of T-Wave Alternans In Patients With CHF**  
*John E. Madias*, Elmhurst Hospital Center, Elmhurst, NY, U.S.A.

**CRT In Patients who do not Conform to the Official Guidelines**  
*I Eli Ovsyshcher*, Ben Gurion University, Beer-Sheva, Israel

**Management and Evaluation of Heart Failure after Cardiac Resynchronization Therapy**  
*Juan M. Aranda, Jr.*, University of Florida College of Medicine, Gainesville, FL, U.S.A.

## **ADVANCES IN CONGENITAL HEART DISEASE**

**Sudden Death and Exercise in Patients with Native or Surgical Corrected Chd (Congenital Heart Disease)**  
*Luciano Daliento*, University of Padua, Padova, Italy

**Outcomes in Adult Congenital Heart Disease**  
*Geoffrey Rosenthal*, The Children's Hospital at the Cleveland Clinic, Cleveland, OH, U.S.A.

**New Perspectives in MRI in Congenital Heart Disease**  
*Titus Kuehne*, Department of Congenital Heart Disease, Berlin, Germany

**Arrhythmias in Adult Congenital Heart Disease**  
*Louise Harris*, University Health Network, Toronto ON, Canada

**Three-Dimensional CT Scanning: A Routine Comprehensive Diagnostic Tool for Congenital Heart Disease**  
*Phalla Ou*, Hopital Necker-Enfants Malades, Paris, France

## **VALVULAR HEART DISEASE / HEART VALVW SURGERY / DISEASES OF THE THORACIC AORTA**

**How Does Acute Aortic Dissection Pick a Time to Occur?**  
*John A. Elefteriades*, Yale University School of Medicine, New Haven, CT, U.S.A.

**Therapeutic Strategy of Acute Aortic Intramural Hematoma**

*Shuichiro Kaji*, Kobe General Hospital, Kobe, Japan

**Medical Therapy for Valvular Diseases - Is it Hope or Reality?**

*Jeffrey S. Borer*, The New York Hospital, Cornell Medical Center, New York, NY, U.S.A.

**New Insights into the Diagnosis and Treatment of Aortic Stenosis**

*Philippe Pibarot*, Hospital Laval Research Center, Sainte-Foy, Quebec, Canada

**Bicuspid Aortic Valve: Valvular and Vascular Implications**

*Pompilio Faggiano*, Spedali Civili, Brescia, Italy

**Phen-Fen Valvulopathy 10 Years Later: What Have We Learned?**

*Neil J. Weissman*, Washington Hospital Center, Washington, DC, U.S.A.

**Ischemic Mitral Regurgitation Treated with External Counterpulsation**

*Yzhar Charuzi*, UCLA School of Medicine, Los Angeles, CA, U.S.A.

**Possibilities and Limitations of Aortic Valve Reconstruction**

*Hans-Joachim Schafer*, University Hospital Homburg, Homburg, Germany

**Where Do We Stand with the Stentless Aortic Valves?**

*Francois Dagenais*, Laval Hospital, Sainte-Foy, Quebec, Canada

**EMERGING ROLE OF PERCUTANEOUS VALVE REPAIR AND REPLACEMENT**

**Transcatheter Valve Replacement and Repair**

*John G. Webb*, St. Paul's Hospital, Vancouver, B.C. Canada

**Percutaneous Mitral Valve Repair: Concept to Reality**

*Saibal Kar*, Cedars-Sinai Medical Center, Los Angeles, CA, U.S.A.